2023 World Conference on Lung Cancer (Posters)-P2.14. First-Line Envafolimab plus Carboplatin-etoposide in Extensive-Stage Small-Cell Lung Cancer: a Single-Arm Phase II Study

P2.14. First-Line Envafolimab plus Carboplatin-etoposide in Extensive-Stage Small-Cell Lung Cancer: a Single-Arm Phase II Study - PDF(Abstract)

Back to course

Pdf Summary

In a Phase II study, researchers investigated the efficacy and safety of first-line treatment with envafolimab plus carboplatin and etoposide in patients with extensive-stage small-cell lung cancer (ES-SCLC). The study included 32 patients who had not previously received treatment. Patients received four cycles of carboplatin and etoposide with envafolimab, followed by maintenance therapy with envafolimab until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS). The secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. <br /><br />As of March 31, 2023, the study reported a median PFS of 6.2 months and an ORR of 84.4%. The DCR was 96.9%, indicating that the treatment was effective in controlling the disease. Of the 32 patients, 1 achieved a complete response, 26 had a partial response, and 4 had stable disease. The most common treatment-emergent adverse events (TEAEs) were grade 1-2 and included anaemia, decreased white blood cell count, hypothyroidism, hypokalemia, and increased liver enzyme levels.<br /><br />The study concluded that first-line treatment with envafolimab plus carboplatin and etoposide showed significant efficacy and manageable toxicities in patients with ES-SCLC. This combination therapy provides a novel therapeutic strategy for these patients. Envafolimab is a subcutaneously administered, humanized camel-derived single-domain anti-PD-L1 antibody that has demonstrated activity in previous phase III trials for ES-SCLC.<br /><br />This research contributes to the understanding of treatment options for patients with ES-SCLC and highlights the potential benefit of combining immunotherapy with chemotherapy. It provides evidence for the efficacy and safety of envafolimab in this patient population and offers hope for improved outcomes in the future.

Asset Subtitle

Shengjie Sun

Meta Tag

Speaker Shengjie Sun

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

Phase II study

efficacy

safety

first-line treatment

envafolimab

carboplatin

etoposide

extensive-stage small-cell lung cancer

progression-free survival

combination therapy